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Background: Stroke may be a clinical expression of several inherited disorders in humans. Recognition of the
underlined genetic disorders causing stroke is important for a correct diagnosis, for genetic counselling and,
even if rarely, for a correct therapeuticmanagement.Moreover, the genetics of complex diseases such the stroke,
in whichmultiple genes interact with environmental risk factors to increase risk, has been revolutionized by the
Genome-Wide Association Study (GWAS) approach.
Scope of review:Herewe review the single-gene causes of ischemic stroke, bringing the reader from the candidate
gene method toward the exciting new horizons of genetic technology.
Major conclusions: The aetiological diagnosis of ischemic stroke in young adults is more complex than in the el-
derly. The identiﬁcation of a genetic cause is important to provide appropriate counseling and to start a correct
therapy, when available. The advent of GWAS technology, such as for other complex pathological conditions,
has contributed enormously to the understanding of many of these genetic bases. For success large, well
phenotyped case cohorts are required, and international collaborations are essential.
General signiﬁcance: This review focuses on themain causes of genetically-based ischemic stroke in young adults,
often classiﬁed as indeterminate, investigating also the recentﬁndings of theGWAS, in order to improve diagnos-
tic and therapeutic management.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Despite substantial progress in prevention and treatment, stroke re-
mains a very relevant condition representing the ﬁrst cause of adult dis-
ability [1], the second cause of dementia [2,3] and the third cause of
mortality in developed countries [4,5]. Therefore, increasing our under-
standing of the risks, causes and treatment of ischaemic stroke is of
great importance.
Only in Italy, every year there are about 196,000 new cases of stroke:
among these about a 20% dies in the following month and about 30%
survives with disabling consequences [6,1,7]. The incidence of stroke
rises exponentially with age, and is quite low in young adults [8]. How-
ever, ischemic stroke is a common cause of admission of young patients
in stroke units [9,10]. In particular, the yearly incidence of stroke in-
creased from 2.4 per 100,000 for people aged 20–24 years, to 4.5 per
100,000 for people aged 30–34 years, and to 32.9 per 100,000 for people
aged 45–49 years. Stroke is slightly more frequent in women aged
20–30 years and in men older than 35 years [9].
Traditional risk factors for stroke such hypertension and diabetes
and pathological conditions like large extracranial and intracranial ath-
erosclerosis, small vessel disease and atrial ﬁbrillation, which play an
important role in older patients, aremuch less frequent in young adults;
therefore, the main clinical challenge in management of a young adult
with stroke is the identiﬁcation of its cause,which often (35% to 42%) re-
mains undetermined [11].
Stroke is believed to be a complex multifactorial and polygenic dis-
ease, arising from a wide number of gene-gene and gene-environment
interactions. Genetic factors could act by predisposing to conventional
risk factors, by modulating the effects of those risk factors on the target
organs or, conversely, by a direct independent effect on stroke risk and
on infarct evolution.
The proportion of strokes of undetermined or rare causes is much
higher for young adults than for elders, and in many cases underlying
causes are genetic-related. The clearest evidence that genetics may
cause ischemic stroke comes from monogenic forms of the disease,
although these account for only a relatively small percentage of overall
ischaemic strokes. In most cases, it is likely that multiple genes are in-
volved in stroke pathogenesis acting on a wide range of candidateTable 1
Common mutations in monogenic diseases for details see the text.
Monogenic diseases Involved genes Genes functions
MELAS tRNA (Leu) A3243G Mitochondrial tRN
tRNA (Leu) T3271C Mitochondrial tRN
tRNA (Lys) A8344G Mitochondrial tRN
Familial hemiplegic migraine CACNA1A Encoding the alph
CADASIL NOTCH3 Unknown
CARASIL HTRA1 Protease
FABRY α-GAL A Encoding α-galac
Small vessel disease COL4A1 Encoding the α1[I
HERNS TREX1 Encoding three-pr
Stroke and vasculopathy
with ADA2 mutations
CECR1 Encoding the ADA
and leukocyte dev
Homocystinuria Multiple genes encoding
different enzymes
Deﬁciencies of thi
concentrations of
Sickle cell disease Haemoglobin beta chain gene Encoding for beta
polymerization or
Vascular Ehlers-Danlos syndrome COL3A1 Encoding collagen
Marfan syndrome FBN1 Encoding ﬁbrillin
Pseudoxanthoma elasticum ABCC6 ATP-binding cassepathways, such as the haemostatic and inﬂammatory system, homocys-
teine metabolism, rennin angiotensin aldosterone system, and so on
[revised in 12,13]. Genetic investigation of individuals who have had a
stroke is a promising approach for identiﬁcation of novel biological
mechanisms that underlie the development of cerebrovascular disease.
Thanks tomodern advances in theﬁeld of stroke genetics,many cases of
cryptogenic stroke have been clariﬁed; the discovery of new pathoge-
netic pathways might lead in the future to the development of preven-
tive strategies and acute treatments [14,15]. The genetic component is
more prevalent in large-vessel ischemic stroke than in small-vessel or
cryptogenic ischemic stroke [16], and in patients younger than
70 years of age [17]. Multicentre studies concluded that siblings usually
develop the same stroke subtype. These ﬁndings have been conﬁrmed
and extended by studies in which the heritability of ischemic stroke
was calculated from genome-wide data, giving estimates of 40% for
large-vessel ischemic stroke, 33% for cardioembolic stroke, 16% for
small-vessel ischaemic stroke, and 38% for the combined endpoint of
any ischemic stroke [18,19].
In this review, themost well-characterized monogenic disorders as-
sociated with stroke will be cover. Recent advances in both common
polygenic conditions associated with stroke and GWA available reports
will also be presented.2. Monogenic diseases
Monogenic diseases are responsible of about 5% of stroke cases [20].
However, the percentage is likely to be underestimated because of the
diagnostic complexity and the high phenotypic variability of these con-
ditions. There are more than 50 monogenic diseases that can cause
stroke [20] [see Table 1]. Recognition of individuals and families carry-
ingmutations causingMendelian or mitochondrial diseases with stroke
as a phenotypic manifestation remains an important challenge for clini-
cians. Mendelian disorders can be recognised by their familial aggrega-
tion, relatively young age of onset, more severe clinical course, and
higher recurrence rates, compared with sporadic diseases. Vice versa,
mitochondrial-related strokes may be maternally inherited, frequently
multi-systemic and life-threatening.References
A [21,22]
A [23]
A [24]
a1A sub-unit of the voltage-gated calcium channels in neurons [39]
[40]
[40]
tosidase A enzyme
V]-chain of type IV collagen [40]
ime repair exonuclease 1 [40]
2 protein (important for endothelial
elopment and differentiation)
[63]
s enzymes can cause very high plasma
homocysteine and homocystinuria
[12]
chain of normal haemoglobin (mutation of this gene causes
aggregation of abnormal hemoglobin -. HbS - within red blood cells)
[39]
type III [12]
1 [65]
tte C6 [66]
Table 2
Common variants in polygenic diseases. For details see the text.
Gene Polymorphism Genes functions References
MTHFR C677T This polymorphism is associated with high levels of plasmatic homocysteine [69]
ACE I/D situated in intron 16 ACE is a membrane-bound enzyme which plays an important
role within the renin-angiotensin aldosterone system
[71–75]
AGT M235T AGT is a glycoprotein substrate for renin action. This polymorphism is associated
with increased blood pressure, carotid plaques and white matter lesions
[76–78]
Prothrombin gene c.20210G4A This mutation is associated with increased prothrombin levels [79]
Fibrinogen gene c.455G4A Possible association between ﬁbrinogen polymorphisms, high ﬁbrinogen levels and arterial thrombosis [13]
FV c.1691G4A This mutation leads to a p.Arg506Gln amino- acid change, which determines
a resistance to aPCR (activated protein C), a stroke predisposing condition
[13]
PAI-1 (SERPINE1) 4G/5G PAI-1 is a fast acting inhibitor of tissue plasminogen (t-PA), which plays a key
role in ﬁbrinolytic homeostasis (mutations cause increased thrombotic risk)
[80,98]
APOE ε2/ε3/ε4 This polymorphisms may have an impact on total cholesterol, LDL and apoE plasma levels [108–110]
PON1 Q192R Alteration of enzyme activity associated with this SNP may inﬂuence the formation of atheromas [114,70]
MMP-3 5A/6A Homozygosity for 6A allele is responsible of a lower proteolytic activity with an
increased deposition of extracellular matrix and a faster progression of the atherosclerotic plaque
[117]
EAAT2 A-to-C change at 181 bp from
the transcriptional start site
The mutant genotype is associated with increased plasma glutamate concentrations [137]
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usually sufﬁcient to manifest a phenotype. However, an incomplete
penetrance may be observed, and not all the subjects carrying the
mutation may manifest a complete phenotype. Moreover, a clear
genotype-phenotype correlation is very rarely observed in monogenic
strokes. At least two genetic phenomenon can inﬂuence the phenotype
in both heterozygosity and homozygosity: the already described incom-
plete penetrance and a variable expressivity, which refers to the type,
severity and natural history of the disease. Among the factors inducing
the variable expressivity, the type of allelic mutation (complete absence
of the encoded protein rather than reduced function), the allelic hetero-
geneity (different mutations in the gene), the interaction with other
genes (pleiotropy) or with environment are the most documented
ones. In X-linked diseases, the clinical expression in females is possible,
and the severity of the phenotype is caused by the phenomenon of X in-
activation (‘mosaicism’).
In mitochondrial DNA (mtDNA) related diseases, the complexity of
the clinical phenotypes and of the genotype-phenotype correlation is
even more problematic. Cells have variable amount of mitochondria,
each of which contains multiple (polyplasmy) identical (homoplasmy)
copies of mtDNA. Mutations located in all the mitochondrial genomes
are deﬁned homoplasmic. Although in the recent years a new interest
is growing about the pathogenic role of homoplasmic mutations (that
can be responsible for heterogeneous disorders with extremely variable
penetrance), they are frequently silent polymorphisms. Differently,
heteroplasmic mutations, which are harboured only from a part of
mtDNA genomes, are often responsible for disease phenotypes. Mole-
cules ofmutated andwild-typemtDNA coexist in the same cell andmu-
tated genomes are distributed randomly to the daughter cells, so that
their amount is different in themitotic cycles (differentmitotic segrega-
tion). Symptoms usually appear whenmutated mtDNAs, following suc-
cessive mitoses, will be enough to cause energetic failure (threshold
effect) [12]. The percentage of mutated genomes able to give rise to
the disease is different from tissue to tissue. Therefore, age of onset
and clinical picture will depend on the amount of mutated genomes
and their distribution in the various tissues.
2.1. Mitochondrial diseases
“MELAS” (Mitochondrial encephalomyopathy with lactic acidosis
and stroke-like episodes) is one of the most common maternally-
inherited mitochondrial disease. A number of point mutations have
been described in association with MELAS phenotype. Although some
of them are located in polypeptide-encoding genes, especially ND,
more frequently they arise in tRNA genes. Themost frequently reported
mutations associated with MELAS are the A3243G and T3271C in tRNA
Leu (UUR) [21–23]. Other mtDNA mutations may cause stroke-likeepisodes as well, i.e. A8344G mutation [24]. MtDNA heteroplasmy
should be searched in available tissues, especially skeletal muscle and
urinary sediment [25]. Even if rarely, nuclear gene (i.e., POLG [mito-
chondrial polymerase gamma] and PEO1 [mitochondrial helicase
“Twinkle”] genes) mutations can cause a MELAS-like syndrome [26,
27]. Clinical features of MELAS include early onset migraine, seizures,
cognitive impairment, hearing loss and stroke-like episodes; lactic aci-
dosis is frequently associated. Aetiology of stroke-like episodes range
from vasogenic oedema [28], cytopathic toxicity and hyperperfusion
[29] and MRI/MR spectroscopy show lesions with no speciﬁc arterial
territory distribution with a major involvement of temporal, occipital
and parietal cerebral areas [30]. In MELAS patients, the most severe
COX deﬁciency associated with the highest proportion of mutated
mtDNA was observed in the walls of the leptomeningeal and cortical
blood vessels, supporting the hypothesis of vascular mitochondrial dys-
function in the pathogenesis of stroke-like episodes [31]. Other features
of mitochondrial disorders are muscle weakness, exercise intolerance,
eyelid ptosis, short stature, pigmentary retinopathy, axonal multifocal
neuropathy, sensorineural hearing loss, ophthalmoparesis, migraine,
optic neuropathy, diabetes mellitus, hypertrophic cardiomyopathy and
Wolff-Parkinson-White syndrome [25,32]. Typical histological ﬁndings
in muscle samples are ragged red and/or COX-negative ﬁbers. Very re-
cently, our group, in collaboration with the Italian Network for mito-
chondrial diseases, observed for the ﬁrst time that male gender could
represent a risk factor for the development of stroke-like episodes in
Italian 3243A N G carriers [32]. To date, no therapy is available to treat
MELAS patients [33]. Most therapeutic strategies to treat this condition
use supplements and enzyme cofactors to enhance mitochondrial me-
tabolism and activity of the respiratory chain [34]. The treatment of
choice may be represented by the combination of L-arginine (usually
applied intravenously at a dosage of 0.4–0.5 g/kg in the acute phase
and then switched to long-term oral supplementation) [33,35], carni-
tine and coenzyme Q10, plus corticosteroids for the vasogenic oedema
and anti-epileptic drugs or other supportive treatments when needed
[36]. Other molecules such as creatine and idebenone have been sug-
gested to decrease lactic acid levels and reduce stroke-like episodes
[37,38]. Treatment options and drugs with potential mitochondrion-
toxic actions (i.e., valproic acid, metformin, linezolid, etc.) have been re-
cently reviewed [36].
2.2. Familial hemiplegic migraine
Familial hemiplegic migraine may be responsible of stroke-like epi-
sodes particularly in childhood and in teenage years. About 50% of
cases are determined by mutations in the CACNA1A gene, encoding
the alpha1A sub-unit of the voltage-gated calcium channels in neurons.
Typical clinical feature is hemiparetic, sensory, visual or dysphasic long-
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and stroke-like episodes or coma are possible complications, even if
neuroimaging (in particular MRI) does not show white matter abnor-
malities or sub-cortical strokes. Treatment options to ﬁght attacks
include intranasal ketamine and intravenous verapamil [39].
2.3. Cerebral autosomal dominant (CADASIL) (and recessive-CARASIL)
arteriopathy with subcortical infarcts and leukoencephalopathy
Cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL), caused by dominant mutations
in the NOTCH3 gene [40], is now recognised as the most common
cause of hereditary cerebral small-vessel disease and vascular cognitive
impairment in young adults [41]. The diagnosis is suspected if there is a
family history and if MRI shows the characteristic conﬂuent subcortical
white matter changes extending to the temporal lobes; conﬁrmation
comes from skin biopsy andgenetic testing [40,41]. Patients can clinical-
ly present with disorders ranging from migraine with aura (20-40%),
ischemic events (strokes or transient ischemic attacks, 60-80%), subcor-
tical vascular dementia, seizures and mood disturbances, despite the
lack of well deﬁned risk factors [42–44]. The estimated prevalence of
CADASIL in young patients with stroke is low (0.5% of lacunar strokes;
2% in patients younger than 65 years with white matter changes) [45]
butmost likely is underestimated. Somemodiﬁable vascular risk factors
such as hypertension and smoking are associated with an increased
probability of stroke in patients with CADASIL, suggesting that these
conditions might modulate the clinical expression of the disease. Accu-
mulation of granular osmiophilic material within the tunica media are
suggestive pathological markers of CADASIL, which lead to luminal ste-
nosis in cerebral arteries and consequent reduction in cerebral blood
ﬂow, mainly in the subcortical white matter [46]. Neuroimaging
shows ischemic lesions in the basal ganglia, periventricular white mat-
ter and temporal lobes [47]. Although there is no real cure for CADASIL,
prevention of ischaemic attacks is commonly based on treatment of
vascular risk factors and antiplatelet drugs rather than anticoagulants
because of the increased risk of cerebral haemorrhage [41]. However,
the beneﬁts of platelet antiaggregates for CADASIL have not been
established yet [48].
Cerebral autosomal recessive arteriopathy with subcortical infarcts
and leukoencephalopathy (CARASIL) or Maeda syndrome [49], due to
mutations in the protease HTRA1, is clinically similar to CADASIL but
with earlier onset (third or fourth decade of life) and systemic symp-
toms, including alopecia, arthropathy, and spondylosis deformans
[40]. This condition is predominant in males. Brain MRI shows diffuse
white matter changes and multiple lacunar infarctions in the basal
ganglia and thalamus [49]. Histopatologically, small vessels in cerebral
white matter and basal ganglia undergo arteriosclerotic changes
resulting in luminal stenosis and loss of arterial smooth muscle, in the
absence of granular osmiophilic or amyloid material [40,50].
2.4. Fabry disease
Fabry disease is a X-linked congenital lysosomal storage disorder
caused by partial or total deﬁcit ofα-galactosidase A enzyme. This path-
ological condition presents incomplete penetrance and variable expres-
sivity, higher in males [51], and is characterized by a progressive
accumulation of glycosphingolipids (particularly globotriaosylceramid
and galactosylceramide) within many tissues and cell types including
vascular endothelial cells, kidney, heart and neurons, with progressive
multiorgan involvement. Tissue damage is thought to be at least partly
due to poor perfusion [52] and themost frequent clinical consequences
are renal failure, hypertrophic cardiomyopathy, and stroke [53]. Gastro-
intestinal symptoms, hypohidrosis, angiokeratomas, corneal opacities
(cornea verticillata), neuropathic pain are also common and may help
in the diagnostic approach [52]. Neurological symptoms are wide-
ranging with the most common presentation being peripheral smallﬁber painful neuropathy also with gastrointestinal symptoms [23,54,
55]. Ischemic stroke and TIA are also common presentations, leading
to cerebrovascular events at an early age [56]. The intracranial posterior
arteries are frequently involved; the most prominent MRI ﬁndings are
severe progressive white-matter lesions and coexistence of large-
vessel and small-vessel disease with torturous and dilated large vessels
(dolichoectasia) [56]. Thewell recognised “pulvinar sign” (T1-weighted
hyperintensity in the pulvinar nucleus of thalami), when present is also
suggestive of this disease [57]. Atypical neurological presentations
(e.g., transient global amnesia [TGA]-like episodes) are rare but possible
[58]. The diagnosis in symptomatic men can be conﬁrmed by a deﬁcit in
serum α-galactosidase, and genetic testing, particularly in women who
usually have normal α-galactosidase activity [59]. The availability of an
effective therapy (α-galactosidase enzyme replacement therapy) has
led to a great interest in Fabry's disease as a cause of stroke in young
adults, however the risk of stroke remains substantial andmanagement
of conventional risk factors is important as well as prompt enzyme sub-
stitution therapy [60,61].
2.5. Other rare autosomal dominant small-vessel diseases
Small vessels disease associated with COL4A1 (encoding the α1[IV]-
chain of type IV collagen) mutation present with infantile hemiparesis,
seizures, migraine, visual loss, dystonia, ischemic and hemorrhagic
strokes, mental retardation, cognitive impairment and dementia [40].
Magnetic resonance imaging (MRI) shows diffuse leukoencephalopathy
with deep white matter involvement of posterior periventricular areas,
subcortical infarcts and microbleeds [62]. A subset of individuals with
COL4A1mutations are reported to have a distinct systemic phenotype,
usually with asymptomatic brain pathology, referred to as hereditary
angiopathy with nephropathy, aneurysms and cramps (HANAC) syn-
drome. The mutations in these patients cluster in a 31-amino-acid re-
gion of the COL4A1 protein that encompasses integrin binding sites.
Hereditary endotheliopathy with retinopathy, nephropathy, and
stroke (HERNS) is causedbymutations of the TREX1 (three-prime repair
exonuclease 1) gene, and is clinically characterised by psychiatric symp-
toms, dementia, subcortical strokes, and leucoencephalopathy. The
onset is usually in the fourth or ﬁfth decade of life. Ophthalmological
ﬁndings – telangiectasias, microaneurysms and retinal capillary obliter-
ation starting in the macula- are common. MRI shows contrast-
enhanced lesions in the white matter of the cerebrum and cerebellum
[40].
2.6. Homocystinuria
Homocystinuria represents a group of mostly autosomal recessive
enzyme deﬁciencies (e.g. cystathionine betasynthase), which cause
very high (N100 μmol/L) plasma concentrations of homocysteine and
homocystinuria [12]. The disease should be considered in patients
with early stroke, mental retardation, dislocation of the ocular lenses,
andMarfan-like skeletal abnormalities. Homocystinuria must be distin-
guished from milder (15–100 μmol/L) hyperhomocysteinemia, a well
documented risk factor for stroke in the general population and associ-
ated with deﬁcient dietary B6, B12, or folate [12]. Homocystinuria can
cause stroke through atherosclerosis and thromboembolism, small-
vessel disease and arterial dissection. Early diagnosis of homocystinuria
is essential because complications can be reduced through vitamin B6
administration [12].
2.7. Stroke and vasculopathy associated with ADA2 mutations
Loss-of-function mutations in CECR1, encoding the ADA2 protein,
are associated with a spectrum of vascular and inﬂammatory pheno-
types, ranging from early-onset recurrent stroke to systemic vasculopa-
thy or vasculitis. ADA2, produced by myeloid cells, is an adenosine
deaminase-related growth factor, which is important for endothelial
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expressed in endothelial cells, in patients with ADA2 mutations there
is a defect in endothelial integrity in the small vessels as well as impair-
ment of M2 macrophage differentiation. Deﬁciency of this protein may
compromise endothelial integrity while polarizing macrophage and
monocyte subsets toward proinﬂammatory cells, establishing a vicious
circle of vasculopathy and inﬂammation. Therapeutic strategies for the
treatment of patients with ADA2 deﬁciency require investigation.
Since ADA2 is found in plasma, these patients may beneﬁt from fresh-
frozen plasma or recombinant ADA2, or, alternatively, given that mono-
cytes and macrophages, the main producers of ADA2, are derived from
bonemarrow, it is possible that bonemarrow transplantation or genetic
manipulation of bonemarrow cells might play a role in the treatment of
these patients [63].
2.8. Sickle cell disease
Haemoglobin S (HbS) results from a substitution of thymine for
adenine in the beta chain gene of haemoglobin. Sickle cell disease
is due to a homozygous or a compound heterozygous state with
HbS occurring in combination with other haemoglobinopathies
[39]. The disorder is most prevalent in patients of African or African
American. The mutation causes polymerization or aggregation of ab-
normal hemoglobin within red blood cells. Patients commonly have
compensated hemolytic anemia, mild jaundice, and vaso-occlusive
crises that cause excruciating pain in the back, chest, and extremi-
ties. Transient ischaemic attacks, ischaemic and haemorrhagic
strokes, seizures and spinal cord vascular events occur in ≈ 25% of
individuals by age 45 years [39]. Treatment options include repeated
transfusions, hydroxyurea and in some instances bone marrow
transplantation [39].
2.9. Disorders of the connective tissue associated with stroke
Ischemic stroke is a well-known complication of several other heri-
table connective tissue disorders, which can be responsible of large-
vessel diseases. Here we consider only the more frequent conditions,
butmany other hereditary connective tissue diseasesmay be associated
with stroke [64].
- Vascular Ehlers-Danlos syndrome
Vascular type of Ehlers-Danlos syndrome (type IV) is an autosomal
dominant disorder resulting from mutations in the collagen III
gene (COL3A1), the gene for collagen type III. Themore common ce-
rebrovascular complications include intracranial aneurysms, arterial
dissection, and spontaneous rupture of large and medium-sized ar-
teries [12].
- Marfan syndrome
Marfan syndrome is an autosomal dominant disorder affecting the
musculoskeletal and cardiovascular systems caused by mutations in
the ﬁbrillin 1 (FBN1) gene. Cerebrovascular complications of the
disease include transient TIAs, ischemic strokes, and subdural
haematoma [65]. Associated clinical features include pectus carinatum
or excavatum, reduced upper-to-lower-segment ratio or increased
arm-span-to-height ratio, scoliosis, ectopia lentis, dilation or dissec-
tion of the ascending aorta, lumbosacral dural ectasia [65]. The associ-
ation of ischemic neurovascular events with cardioembolism and/or
aortic and cerebral artery dissection is still debated.
- Pseudoxanthoma elasticum
Ischaemic stroke has also been recognised as a complication of
pseudoxanthoma elasticum, a recessive disease (rarely dominant)
due to ABCC6 (ATP-binding cassette C6) gene mutations, which is as-
sociatedwith small-vessel disease and stenotic lesions of the distal ca-
rotid artery. Associated features include skin changes (increased
elasticity and yellow-orange papular lesions), ocular abnormalities
(angioid streaks) and hypertension [66].3. Polygenic conditions
Single-gene disorders explain only a minority of stroke cases; stroke
represents a complex condition, wheremultiple genes and the environ-
ment are involved. In this scenario, the role of a great number of candi-
date genes has been investigated through association studies, with
controversial results [see Table 2].
In polygenic and polyfactorial diseases, multiple genetic and envi-
ronmental factors are both necessary to reach a treshold level, critical
for the phenotype manifestation. However, while in monogenic condi-
tions the genetic counselling is usually sufﬁcient to quantify the risk of
inheritance of the speciﬁc disease, in a polygenic scenario this is not
the case. The individual risk and the subsequent natural history of the
disease cannot be predicted even knowing the single genetic variant(s),
being that potentially modiﬁed by other conditions, i.e. lifestyle or co-
morbidities. Therefore, to date it is difﬁcult for the clinician to establish
the validity and the level of clinical applicability of the associations be-
tween such genetic factors and stroke [13].
3.1. Homocysteine metabolism
Plasma levels of homocysteine, a sulphidryl-containing amino acid
derived from themetabolism of methionine, increase with some condi-
tions such as age, vitamin B12, B6, and folate deﬁciency, or renal dys-
function [67]; other less clear cause of hyperhomocysteine are
smoking, arterial hypertension, hypercholesterolemia, coffee and alco-
hol consumption [67]. As reported above, hyperhomocysteinemia is
an independent risk factor for ischaemic stroke [68]. A common func-
tional polymorphism of MTHFR, C677T, has been found to be associated
with differences in homocysteine concentration (about 1.93 μmol/l be-
tween TT and CC homozygotes) [69]. Most studies show the causal rela-
tionship between homocysteine concentration and stroke. Severe
hyperhomocysteinemia (4100 mmol/l), linked to homocystinuria, has
been previously treated (“Monogenic Diseases” paragraph). Mild to
moderate hyperhomocysteinemia (515–100 mmol/l) occurs in pheno-
typically normal subjects with genetic defects (heterozygosity of
MTHFR or cystathionine-b-synthase –CbS-), acquired conditions, or an
association of both. At least 60 mutations have been recognized on the
CbS gene, of which the most common ones are the nucleotides change
c.833C4T (resulting in p.Ile278Thr) and the c.919G4A (p.Gly307Ser),
both in exon 8, and the splice alteration c.844 ins68. However, the
most common gene variant associated with moderate hyperhomocys-
teinemia is the substitution c.677C4T of the gene encoding forMTHFR,
mappedon chromosome1p36.3, resulting in a p.Ala222Val substitution.
This molecular variant is responsible for the reduction of 50% of
enzymatic activity [13]. Some studies indicate a synergistic interaction
between MTHFR and lipid metabolism in the development of
atherothrombotic stroke [70].
3.2. Renin-angiotensin-aldosterone system
- Angiotensin-converting enzyme (ACE) is a membrane-bound enzyme
which play an important role within the renin-angiotensin aldoste-
rone system; therefore, it is involved in the development of hyper-
tension, atherosclerosis and cardiovascular disease. The ACE gene is
located on chromosome 17q23 and consists of 26 exons. An inser-
tion (I)/deletion (D) polymorphism of 287 bp situated in intron 16
of the ACE gene, so-called ACE I/D polymorphism, has been de-
scribed. The homozygous DD [71,72] was found associated with
high ACE plasma and tissue [73]. ACE gene polymorphisms have
been widely studied in stroke, after the demonstration of increased
risk of myocardial infarction in DD genotype carriers [74]. However,
the role of ACE polymorphism in ischemic stroke is uncertain [75].
- Angiotensinogen (AGT) is a glycoprotein which represents the sub-
strate for renin action. AGT levels contribute to hypertension [76].
The gene encoding for AGT is located on chromosome 1. The most
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onine at amino-acid position 235 (p.Met235Thr) and the amino-acid
change methionine for threonine at 174. Some studies found an as-
sociation between angiotensinogen p.Met235Thr and increased
blood pressure, carotid plaques, and white matter lesions, suggest-
ing that AGT gene variants could act at an intermediate phenotype
level [77]. In addition, the AGT 235 T allele has been reported to con-
tribute to salt sensitivity [78]. However, the effect of the AGT gene
polymorphisms on the risk of ischemic stroke remains controversial.
3.3. Hemostasis (coagulation and ﬁbrinolytic system)
Genes involved in the hemostatic mechanism are logical candidate
genes in prothrombotic conditions of stroke [70].
- Prothrombin. Prothrombin (proenzyme of thrombin) is a vitamin K–
dependent glycoprotein that converts ﬁbrinogen into ﬁbrin. The
gene coding for prothrombin is located on chromosome 11p11–
q12 and consists of 14 exons. Poort and colleagues [79] identiﬁed a
single-nucleotide G4A transition, at position 20210 (c.20210G4A)
in the prothrombin gene, associated with increased prothrombin
levels. This variant has been correlated to an increased risk of venous
thrombosis [80–82] and stroke [83].
- Fibrinogen. A glycoprotein composed of three polypeptidic chains
named a, b, and g, encoded by different genes: FGA, FGB and FGG,
clustered on the long arm of chromosome 4q28. This glycoprotein
was considered for a long time an independent risk factor not only
for stroke but also for myocardial infarction and peripheral vascular
diseases [84]. The relation between the c.455G4A polymorphism
and thrombotic disease is still unclear, even though a possible asso-
ciation between ﬁbrinogen polymorphisms and high ﬁbrinogen
levels and arterial thrombosis has been postulated [13].
- Factor V Leiden (FV) is a large single-chain glycoprotein, encoded by a
gene mapped on chromosome 1q23, involved in the coagulation
process and regulated by activated protein C [85]. The FV gene's
most studied polymorphism is the single point mutation
c.1691G4A leading to a p.Arg506Gln amino acid change, which de-
termines a resistance to aPCR (activated protein C), proved to be a
stroke predisposing condition [13].
- Factor VII (FVII) is a vitamin K–dependent coagulation factor
encoded by a gene located on chromosome 13q34, in which ﬁve
polymorphisms have been identiﬁed. It is still unclear whether
these polymorphisms,which are proved to be determinants of circu-
lating FVII concentrations, are associated with arterial thrombosis or
not [86,87]; to date, an association between FVII gene polymor-
phisms and stroke is denied [88].
- Factors XII (FXII) and XIII (FXIII) FXII is a plasma protein involved in
intrinsic pathway of coagulation, ﬁbrinolysis, and kinin formation.
The gene for FXII, is located on chromosome 5q33-qter; a common
SNP is the C-T substitution at nucleotide 46 in the 5′UTR of exon 1
[89], probably responsible for decreased FXII plasma levels. The
role of this variant in venous thrombosis and coronary heart diseases
is still under discussion [90–92] and further studies are needed to
clarify the role of FXII gene variants in the stroke risk.
FXIII is a transglutaminase involved in the ﬁnal step of coagulation
cascade, which consists of two A-subunits (active site) and two B-
subunits (carrier molecule), encoded by genes located on chromosome
6p25–p24 and 1q31–q32.1, respectively. Several polymorphisms of the
A subunit have been described in the gene F13A1 on chromosome 6; of
these, c.143G4T seems to cause FXIII inactivation and could contribute
to thrombotic disorders. However, the association between F13A1
p.Val34Leu polymorphism and ischemic stroke is still unclear [13].
- VonWillebrand factor (vWF) is a glycoproteinwhich promotes plate-
let adhesion and aggregation. Several variants have been identiﬁedin the vWF gene, which is localized on chromosome 12p13.3. How-
ever, none of these variants have a conﬁrmed role in ischemic stroke
[93].
- Plasminogen activator inhibitor 1 (PAI-1) is a fast acting inhibitor of
tissue plasminogen (t-PA), which plays a key role in ﬁbrinolytic
homeostasis. High levels of PAI-1 have been detected in the
atheromatic plaque [94] and have been linked to the development
of myocardial infarction [95]. The human gene for PAI-1 (SERPINE1)
is located on the long arm of chromosome 7. Several polymorphic
loci have been described [80,96,98]; however, most of studies ex-
cluded an association between SERPINE1 variants and stroke [97,70].
3.4. Platelet glycoproteins
- Platelet glycoprotein Ia–IIa complex (GPIa–IIa complex) is the
major platelet/collagen receptor responsible for platelet adhe-
sion to exposed vascular subendothelium. Two SNPs in the gene
for the GPIa subunit, the ITGA2 gene, have been described:
c.807C4T and c.873G4A. Another SNP, c.1648 G-A, which pro-
duces the amino-acid substitution p.Glu505Lys, is responsible
for the HPA-5 platelet antigen system. This polymorphism is al-
ways present together with the c.807C4T variant, providing
three different haplotypes (allele A1, 807C/Glu505; allele A2,
807 T/Glu 505; and allele A3, 807C/Lys 505). Only a few studies
report an increased, although not signiﬁcant, risk of stroke in
young women carrying the c.807C4T polymorphism [98]; vice
versa, other studies do not conﬁrm association between ITGA2
gene variants and stroke risk [87,99].
- Platelet glycoprotein IIb–IIIa complex (GpIIb–IIIa complex) is a re-
ceptor which plays a key-role in platelet activation, aggregation,
and clot formation. The genes encoding for the GpIIb–IIIa com-
plex, named ITGB3 and ITGA2B, are both located on chromosome
17. So far, ITGB3 and ITGA2B genes SNPs do not seem to be associ-
ated with ischemic stroke [100,101].
c) Platelet glycoprotein Ib/IX/V complex (GPIb/IX/V complex) is the
major platelet receptor for von Willebrand factor. Several poly-
morphisms have been characterized in the four genes encoding
for the complex, mostly in the gene encoding for GPIba subunit
(GP1BA), located on chromosome 17. The rs41439349 polymor-
phism, characterized by variable numbers of tandem repeats,
cause a replication of a 13–amino acid sequence (from Serine
399 to Threonine 411) and consequently four different-sized var-
iants D, C, B, A (in order of the increasing number of repeats, from
1 to 4 times) [102]. A second polymorphism identiﬁed in the
GP1BA gene is c.3550C4T, resulting in a p.Thr145Met substitution
linked to the human platelet antigen 2 (HPA-2) alloantigen sys-
tem [103,104]. A possible association between the HPA2 SNP
and stroke, in Japanese stroke patients [105,106] and in a series
of 564 patients meta-analysed by Casas and colleagues [83], has
been proposed. An increased risk of stroke has also been reported
in –5C(T/C) carriers in both Japanese [106] and in Austrian pa-
tients [107].
3.5. Lipid metabolism
- Apolipoprotein E (Apo E). Apo Emodulates themetabolism of athero-
genic lipoprotein particles and is involved in the process of cellular
incorporation of speciﬁc lipoproteins. APOE ε2/ε 3/ε 4 polymor-
phism has been demonstrated to have an impact on total cholester-
ol, LDL and apoE plasma levels (total and LDL-cholesterol levelswere
the highest in apoE ε4 stroke patients and the lowest in ε2 subjects
[108]). Several studies report a possible role of the ε4 allele as a prog-
nostic genetic marker for the atherothrombotic subtype, lacunar
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ported to be associated with lower risk of carothid atherosclerosis
and white matter disease [110,111,70].
- Lipoprotein lipase (LPL). LPL plays a key role in lipid metabolism, hy-
drolyzing triglycerides from chylomicrons and VLDL and removing
chylomicron remnants and VLDLs from the circulation [112,113].
The LPL gene is located on chromosome 8p22. Few studies suggest
that three LPL SNPs seem to increase the risk of ischemic stroke: a
stop mutation Ser447Ter in exon 9 (S447X), the c.1127A4G in
exon 6, resulting in p.Asn291Ser, and the p.Asp9Asn [13].
- Paraoxonase (PON1). PON family has been demonstrated to prevent
lipid peroxidation and consequently exerts antiatherosclerotic ef-
fects. Alteration of enzyme activity due to polymorphisms in the
PON genes may inﬂuence the formation of atheromas and thus in-
crease stroke risk [114,70]. PON1 is a calcium-dependent serum en-
zyme located on HDL. The gene encoding for PON1 is mapped on
chromosome 7q21.3. Two common polymorphisms in the coding
region of the PON1 gene are the p.Glu192Arg and p.Met55Leu.
Even though in some recent studies PON1 seems to have a role in
atherosclerosis and cardiovascular disease, it is still uncertain if
those SNPs may be involved in stroke risk.
3.6. Matrix metalloproteinases (MMPs)
MMPs regulate the accumulation of extracellular matrix during tis-
sue injury through their protolytic activity and have an important role
in vascular remodeling and development of atherosclerotic plaques
[115,116]. In human, increased MMP-3 and MMP-9 expression in
some plaque regions has been observed [70]. The 5A/6A polymorphism
in the MMP-3 promoter region is a widely studied gene locus and most
studies support the hypothesis that homozygosity for 6A allele is re-
sponsible of a lower proteolytic activity with an increased deposition
of extracellular matrix and a faster progression of the atherosclerotic
plaque [117].
3.7. Genome-wide studies: linkage approach
Until very recently, main technique used to identify underlying ge-
netic predisposing conditions for ischemic stroke was the candidate
gene method: SNP(s) are identiﬁed in a proposed candidate gene, and
the frequency of the SNPs in patients with stroke compared with con-
trols was then determined [118].
The genetics of complex diseases, including stroke, has been rev-
olutionized by the advent of the genome-wide association study
(GWAS) approach [15]. This can be thought of as a large series of can-
didate gene studies performed in a single experiment on an array
based format [119]. A great advantage of GWAS approach is that it al-
lows associations between completely novel chromosomal loci and
disease [118]. GWAS have provided the strongest evidence for loci
associated with the common form of ischemic stroke. Most of the
loci have been discovered in other related conditions such as atrial ﬁ-
brillation, coronary disease, and coagulation, and subsequent repli-
cation in ischemic stroke patients.
Associations seem to be speciﬁc to subtypes of ischemic stroke; for
example, a locus on chromosome4q25 adjacent to the transcription fac-
tor PITX2 (codes for pituitary homeobox 2, critical for left-right asym-
metry and differentiation of left atrium), found to be associated with
atrial ﬁbrillation, was subsequently found to be associated with cardio-
embolic stroke [120]. Rs1906591 and rs10033464 were analyzed in six
studies including a total of 4199 stroke patients and 3750 controls of
Caucasian ethnicity, revealing a signiﬁcant relationship with cardioem-
bolic stroke and atrial ﬁbrillation only for the ﬁrst SNP [121]; data were
consistentwith a following case-control study in a Han Chinese popula-
tion of 1486 subjects [122].Additionally, a locus on chromosome 16q22 involving ZFHX3 (the
zinc ﬁnger homeobox protein 3) has been associated with both atrial ﬁ-
brillation and cardioembolic stroke [120,123]. Similarly, a pooled analy-
sis demonstrated that 6 SNPs in the chromosome 9p21 locus, ﬁrst
identiﬁed through a heart disease GWAS, are associated with athero-
sclerotic stroke independently of demographic variables or other vascu-
lar risk factors [124]. Genetic variants identiﬁed through GWASs of
coagulation/ﬁbrin phenotypes were subsequently examined for associ-
ation with ischemic stroke. The rs505922 in the ABO gene was found to
have a replicated association with large-vessel and cardioembolic
stroke. More recently, GWASs of ischemic stroke have identiﬁed novel
loci that were not previously identiﬁed through GWASs of other vascu-
lar diseases.
The SNP rs11984041 in HDAC9 (codes for histone deacetylase 9,
chromosome 7p21) has been associated with large-vessel atheroscle-
rotic stroke [125]. In addition, to conﬁrm ischemic stroke loci initially
identiﬁed in non-stroke GWASs (PITX2, ZFHX3 and the 9p21 locus), a
meta-analysis of theMETASTROKE collaboration, considering 12,389 is-
chemic strokes and 62,004 controls of European ancestry, conﬁrmed the
HDAC9 locus linked to atherothrombotic subtype and the PITX2, ZFH3
loci to cardioembolic subtype [126]. Moreover, HDAC9 variants seem
to relate to the predisposition to atherosclerosis [118]. As with HDAC9,
a novel locus associated with large-vessel ischemic stroke was ﬁrst dis-
covered in a stroke GWAS.
The rs12425791 and rs11833579 inter-genic polymorphisms on
chromosome 12p13, close to theNINJ2 gene (encoding ninjurin 2, a pro-
tein which might have a role on nerve regeneration after a damage)
were associated with an increased risk for all ischemic strokes, stronger
with the atherothrombotic subtype, among 19602 white subjects
followed for 11 years; the replication of the association was observed
testing a Dutch (for both SNPs, rs11833579 only for atherothrombotic
strokes) and a North Black American (only for rs12425791) indepen-
dent samples [127], although, in a meta-analysis of 18294 subjects
(9358 cases, 8936 controls) from 11 studies in Asian populations, the
rs11833579 didn't conﬁrm these results, even analyzing separately Chi-
nese from Japanese patients [128].
Still considering Chinese people, the rs2208454 (located on intron 3
of chromosome20p12, in theMACROD2 gene, coding for O-acetyl-ADP-
ribose deacetylase), which was already known to be related to MRI-
detected brain infarcts [129], has demonstrated association with ische-
mic stroke and, in particular, with large-artery atherosclerosis, in a case-
control study of 1486 subjects (712 cases, 774 controls), adjusting the
analysis for age, hypertension, familial history, diabetes and gender
[122].
A GWAS [130] has also been performed studying the homocyste-
ine blood levels (after a methionine load) in 2710 people from the
Framingham Heart Study (FHS) and 2100 people from the Vitamin
Intervention for Stroke Prevention trial, individuating ﬁve genes as-
sociated with high homocysteine levels; thus, it was evaluated the
association with incident ischemic stroke in the FHS patients, ﬁnding
that only with the SNP rs2364368 in the ALDH1L1 locus (aldehyde-
dehydrogenase-1 family member-1, coding for a protein which con-
verts 10-formyltetrahydrofolate to tetrahydrofolate).
Another recent, small size case-control study in 200 Chinese Han pa-
tients has revealed twonovel susceptibility loci in c-1orf156 gene (chro-
mosome 1q24, rs10489177), with increased ischemic stroke risk in
individual without hypertension and diabetes, and in XYLB gene (chro-
mosome 3p21, rs17118), more related to individual with hypertension,
non-smoker and without diabetes [131].
An overall meta-analysis of 17,970 ischemic stroke cases and 70,764
controls, recruited from WTCCC2 data and METASTROKE consortium
statistics, found a novel association for rs10744777 on the chromosome
12q24, which didn't differ signiﬁcantly in the single stroke subtypes
[132].
Finally, GWAS have been conducted on metalloproteinases (MMP)
loci: it was found a novel association between rs660599 (on MMP12
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and 12095 controls [133]. In the ﬁrst GWAS performed on pediatric
stroke, 270 German families (in which both children and parents were
affected by stroke) were investigated; an association between four
members belonging to ADAMTS (A Disintegrin And Metalloproteinase
with Thrombospondin Motifs) gene family was detected, with SNPs of
ADAMTS2 and ADAMTS12 strongly associated and ADAMTS13 (this
protein critical for von Willebrand factor degradation) and ADAMTS17
moderately associated with ischemic stroke [134].
Despite the above studies and the various associations with overall
ischemic stroke risk and the speciﬁc stroke subtypes observed for
SNPs, the meta-analysis from the CHARGE Risk Score Project [135],
which included 2047 ﬁrst-stroke patients from a baseline stroke-free
population of 22,720, N55 years old subjects of European origin, follow-
ed for twenty years, and elaborated a Genetic Risk Score matching 324
SNPs stroke-related with 9 well-known risk factors, found only a small
improvement in stroke prediction, when considering the GRS added
to the Framingham Stroke Risk Score.
Thus, the NINDS Stroke Genetic Network (SiGN), created in 2009, in
collaboration with the Center for Inherited Diseases Research (CIDR),
recently designed a GWAS to genotype a total of 14,549 European and
US stroke cases, classifying ischemic stroke subtypes with the Causative
Classiﬁcation of Stroke (CCS) system, reducing this way lacks of agree-
ment between the single centres and harmonizing the results [136].
4. Genetic determinants in stroke outcome
Genetic research may be helpful not only to achieve a better under-
standing of susceptibility factors related to stroke, but also to determine
stroke outcome, or response to speciﬁc therapies. Some polymorphisms
could be associated not with an increased stroke risk but with a higher
frequency of neurological deterioration in patients with acute stroke.
This is the case of the polymorphism in the EAAT2 promoter, which
seems to be responsible for the susceptibility to excitotoxicity after
stroke. Mallolas et al. [137] found a highly prevalent polymorphism in
the promoter of the glutamate transporter EAAT2 gene that abolishes
a putative regulatory site for activator protein–2 (AP-2) and creates a
new consensus binding site for the repressor transcription factor GC-
binding factor 2 (GCF2). The mutant genotype is associated with in-
creased plasma glutamate concentrations and with a higher frequency
of early neurological worsening in human stroke.
Common genetic variation also affects themetabolism, plasma avail-
ability, or clinical response of stroke drugs. The CYP2C19*2 variant is as-
sociated with both reduced concentrations of clopidogrel in blood and
increased risk of cardiovascular events in patients receiving this drug
[138]. Similarly, SNPs located in A2M (rs669) and F12 (rs1801020) are
associatedwith haemorrhagic transformation and in-hospital death, re-
spectively, after alteplase [139]. For newer anticoagulants, variants lo-
cated in ABCB1 and CES1 were shown to affect both trough and peak
concentrations of dabigatran. In particular, a CES1 polymorphism signif-
icantly reduces the concentration of dabigatran in blood by15%, and risk
of bleeding was reduced of 33% [140]. However, the molecular studies
related to the new anticoagulant drugs are at their beginning [14].
5. Conclusions
The aetiological diagnosis of stroke in young adults needs a different
and more complex diagnostic work up than in older adults. Progress in
the identiﬁcation of the causes and mechanisms of stroke in young
adults has been slow but constant, mainly because of technological pro-
gresses in neuroimaging and because the explosion of themolecular era.
Identiﬁcation of monogenic stroke is important to provide appropriate
genetic counselling and, even though rarely, to start a correct therapy.
Furthermore, a correct genetic diagnosis might improve clinical care,
because speciﬁc preventive measures can be implemented on the
basis of known natural evolution of some disorders [141].No far from today, pharmacogenetic information to personalise ther-
apeutic decision will be available, because common genetic variation
may predict metabolism, plasma availability and clinical response of
stroke drugs (eg, variant of CYP2C19*2).
Despite the many discoveries described, the main challenge for
stroke genetics is to transform ﬁndings into actionable clinical methods
[14].The advent of new techniques such as GWAS has contributed enor-
mously to the understanding of the genetics of other complex disease
and progress is just beginning to be made in stroke. For success, large,
well phenotyped case cohorts are required, and international collabora-
tions are essential.
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